2019 IPO

Frequency Therapeutics Stock

Small, molecular progenitor cells drugs

Sign up today and learn more about Frequency Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Frequency Therapeutics Stock

Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. The lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone.

Funding History

April 2017$32.0M
May 2018$2.0M
January 2019$42.0M


Co-founder, President and Chief Executive Officer

David L. Lucchino

Co-founder and Vice President, Biology and Regenerative Medicine

Will McLean

Co-Founder, Co-chair of Scientific Advisory Board

Jeff Karp

Chief Operating Officer

Michael Jirousek

Co-founder and Chief Scientific Officer

Chris Loose

Chief Medical Officer

Peter Weber

Senior Vice President, Drug Development and Technical Operations

Raj Manchanda


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: